Schalekamp, T.

patient genotype study alternative drug vkorc fi rst month month cyp 2c warfarin alternative vkorc 1 dosing acenocoumarol pharmacogenetic recommendation dose adjustment response event concentration effect allele group period result number cyp 2c genotypes variant therapy adjustment table plasma wild-type inr range vkorc 1 genotypes treatment carrier range coumarin interaction overanticoagulation gene –drug interaction maintenance dose schalekamp genotyping increase –drug evidence value difference dose adjustments netherland acenocoumarol users phenprocoumon rotterdam university calculation algorithm maintenance *1*1 check inr gene –drug anticoagulation fidence intervals omeprazole genotype-guided maitland-van der zee initiation time periods thromboembolic events cyp 2c genotype percentage pre-eu-pact pharmacogenetic-guided dosing wild-type patients rotterdam study increase dose hla-b utrecht supratherapeutic inr values strategy